Roger S. Newton

7.8k citations

92 papers · 6.5k indexed · 2 hit papers · h-index 43

Surgery top 0.5%
Molecular Biology top 5%
Clinical Biochemistry top 0.1%
Endocrinology, Diabetes and Metabolism top 0.5%
Cancer Research top 2%

Co-authors: Michael Aviram Mira Rosenblat Charles L. Bisgaier Brian R. Krause C L Bisgaier S.L. Primo-Parmo Bert N. La Du Stephen L. Pinkosky
Topics: Lipoproteins and Cardiovascular Health (38 papers)Cholesterol and Lipid Metabolism (25 papers)Peroxisome Proliferator-Activated Receptors (19 papers)
Cited by: Clinical Biochemistry Biochemistry Endocrinology, Diabetes and Metabolism
Journals: Journal of Biological Chemistry Circulation Journal of Clinical Investigation
Partner nations: United States Russia Canada

In The Last Decade

Roger S. Newton

90 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

1998 984 citations Roger S. Newton et al. profile →
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

1999 523 citations Charles L. Bisgaier, Roger S. Newton et al. profile →

Peers

Countries citing papers authored by Roger S. Newton

Since Specialization

Citations

This map shows the geographic impact of Roger S. Newton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger S. Newton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger S. Newton more than expected).

Fields of papers citing papers by Roger S. Newton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger S. Newton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger S. Newton. The network helps show where Roger S. Newton may publish in the future.

Co-authorship network of co-authors of Roger S. Newton

This figure shows the co-authorship network connecting the top 25 collaborators of Roger S. Newton. A scholar is included among the top collaborators of Roger S. Newton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger S. Newton. Roger S. Newton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ETC-1002 LOWERS LDL-C MORE THAN EZETIMIBE IN PATIENTS WITH HYPERCHOLESTEROLEMIA WITH OR WITHOUT STATIN INTOLERANCE AND HAS A SIMILAR SAFETY AND TOLERABILITY PROFILE 2015 ·Journal of the American College of Cardiology ·Paul D. Thompson,Christie M. Ballantyne,James McKenney,David G. Orloff,Diane MacDougall,Janice R. Margulies,Jeffrey C. Hanselman,Roger S. Newton	5
2	Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus 2014 ·Arteriosclerosis Thrombosis and Vascular Biology ·María J. Gutiérrez,(unknown),Diane MacDougall,Jeffrey C. Hanselman,Janice R. Margulies,Poul Strange,Mark A. Milad,Scott McBride,Roger S. Newton	135
3	ETC-1002, A MODULATOR OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AND ADENOSINE TRIPHOSPHATE-CITRATE LYASE, WAS SAFE AND REDUCED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL IN HEALTHY VOLUNTEERS 2013 ·Journal of the American College of Cardiology ·Diane MacDougall,James T. VanderLugt,(unknown),Lorenzo A. DiCarlo,(unknown),Janice R. Margulies,Roger S. Newton	3
4	Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia 2013 ·Journal of the American College of Cardiology ·Christie M. Ballantyne,Michael H. Davidson,Diane MacDougall,Harold Bays,Lorenzo A. DiCarlo,(unknown),Janice R. Margulies,Roger S. Newton	136
5	AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases 2012 ·Journal of Lipid Research ·Rai Ajit K. Srivastava,Stephen L. Pinkosky,С. И. Филиппов,Jeffrey C. Hanselman,Clay T. Cramer,Roger S. Newton	240
6	AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism 2012 ·Journal of Lipid Research ·Stephen L. Pinkosky,С. И. Филиппов,Rahul Srivastava,Jeffrey C. Hanselman,(unknown),Timothy R. Hurley,Clay T. Cramer,Mark A. Spahr,(unknown),Jacob L. Houghton,Chris Baker,Mark Naples,Khosrow Adeli,Roger S. Newton	191
7	Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI–CIII–AIV transgenic mice 2010 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Rai Ajit K. Srivastava,Shirley He,Roger S. Newton	5
8	Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus lovastatin 1995 ·Atherosclerosis ·Bruce J. Auerbach,Brian R. Krause,Charles L. Bisgaier,Roger S. Newton	44
9	Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation 1994 ·Atherosclerosis ·Thomas Bocan,(unknown),Sandra Bak Mueller,(unknown),Drago R. Sliskovic,Patrick O’Brien,(unknown),Helen Lee,Paul D. Uhlendorf,Bruce D. Roth,Roger S. Newton	70
10	Evaluation of Two Novel Biochemicals on Plasma and Egg Yolk Lipid Composition and Laying Hen Performance 1993 ·Poultry Science ·Robert G. Elkin,(unknown),Bruce A. Watkins,Morris Srebnik,Karen A. Kieft,Roger S. Newton	9
11	Lipoprotein lipase-mediated lipolysis of very low density lipoproteins increases monocyte adhesion to aortic endothelial cells 1992 ·Biochemical and Biophysical Research Communications ·Uday Saxena,(unknown),Erika Ferguson,Roger S. Newton	30
12	Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand White rabbits 1992 ·Experimental and Molecular Pathology ·Thomas Bocan,Sandra Bak Mueller,(unknown),Paul D. Uhlendorf,(unknown),Roger S. Newton	31
13	Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones 1992 ·Journal of Medicinal Chemistry ·Drago R. Sliskovic,C. John Blankley,Brian R. Krause,Roger S. Newton,(unknown),W. Howard Roark,Bruce D. Roth,Catherine Sekerke,Maxwell K. Shaw,Richard L. Stanfield	16
14	Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors 1992 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Thomas Bocan,Erika Ferguson,W. McNally,Paul D. Uhlendorf,Sandra Bak Mueller,Peter D. DeHart,Drago R. Sliskovic,Bruce D. Roth,Brian R. Krause,Roger S. Newton	74
15	Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus 1991 ·Journal of Medicinal Chemistry ·Bruce D. Roth,C. John Blankley,Alexander Chucholowski,Erika Ferguson,M. L. HOEFLE,Daniel F. Ortwine,Roger S. Newton,Catherine Sekerke,Drago R. Sliskovic,Michael Wilson	151
16	Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase 1991 ·Journal of Medicinal Chemistry ·Bruce D. Roth,Thomas Bocan,C. John Blankley,Alexander Chucholowski,Paul L. Creger,(unknown),Erika Ferguson,Roger S. Newton,Patrick O’Brien	46
17	Dietary and mechanically induced rabbit Iliac-femoral atherosclerotic lesions: A chemical and morphologic evaluation 1991 ·Experimental and Molecular Pathology ·Thomas Bocan,Sandra Bak Mueller,Paul D. Uhlendorf,Erika Ferguson,Roger S. Newton	25
18	Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles 1990 ·Journal of Medicinal Chemistry ·Drago R. Sliskovic,Bruce D. Roth,(unknown),M. L. HOEFLE,Roger S. Newton	48
19	Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase 1990 ·Biochemical and Biophysical Research Communications ·(unknown),Roger S. Newton,Drago R. Sliskovic,Bruce D. Roth,Erika Ferguson,Brian R. Krause	46
20	Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3(2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure 1989 ·Journal of Medicinal Chemistry ·Ila Sircar,R. Steffen,(unknown),(unknown),Roger S. Newton,Ronald E. Weishaar,James A. Bristol,Dale B. Evans	31

About Roger S. Newton

Roger S. Newton is a scholar working on Biochemistry, Surgery and Cancer Research, having authored 92 papers that have together received 6.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (38 papers), Cholesterol and Lipid Metabolism (25 papers) and Peroxisome Proliferator-Activated Receptors (19 papers). The work is most often cited by research in Clinical Biochemistry (1.8k citations), Biochemistry (812 citations) and Endocrinology, Diabetes and Metabolism (1.5k citations). Roger S. Newton has collaborated with scholars based in United States, Russia and Canada. Frequent co-authors include Michael Aviram, Mira Rosenblat, Charles L. Bisgaier, Brian R. Krause, C L Bisgaier, S.L. Primo-Parmo, Bert N. La Du, Stephen L. Pinkosky, Scott S. Billecke and Robert C. Sorenson. Their work appears in journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact